Comparison of Diuretic Effects between Empagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor With Osmotic Diuresis, and Tolvaptan, a Water Diuretic, in Two Type 2 Diabetic Patients Taking Sodium Diuretics
Journal Title: Diabetes Research – Open Journal - Year 2016, Vol 2, Issue 2
Abstract
Empagliflozin, one of sodium-glucose co-transporter 2 (SGLT2) inhibitors, has been demonstrated to have beneficial effects on cardiovascular morbidity and mortality in patients with type 2 diabetes at high risk for cardiovascular events. The mechanisms behind these benefits of empagliflozin are presumed to include osmotic diuresis, being rather close to water diuresis than sodium diuresis. Two cases are presented here, where distinct changes in urinary water and sodium excretion were seen immediately after replacing tolvaptan, a water diuretic, with empagliflozin. Case 1 with heart failure showed a large decrease in urinary sodium excretion with a slight decrease in urine volume. By contrast, Case 2 with nephrotic syndrome showed a large increase in urinary sodium excretion with an increase in urine volume. The differences were probably due to distinct diuretic effects of empagliflozin and tolvaptan in the presence of sodium diuretics as well as distinct pathological conditions. In addition, the amount of urine protein was reduced after the replacement in Case 2. SGLT2 inhibitors would be expected to have the potential to exert some beneficial effects other than lowering blood glucose levels by increasing urinary glucose excretion.
Authors and Affiliations
Yuji Aoki
Keywords
Related Articles
- EP ID EP550156
- DOI 10.17140/DROJ-2-128
- Views 113
- Downloads 0
Attenuated Efficacy of Dulaglutide in Elder Type 2 Diabetes Mellitus (T2DM) Cases
Acute increase of type 2 diabetes mellitus (T2DM) is a serious medical problem. Recently, an agent known as Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was developed for T2DM which has remarkable efficacy and s...
Advances in Type 1 Diabetes Ocular Remote Tele-Health Screening
Background: Type 1 diabetes affects approximately 3 million Americans. Subjects are on average 14-years-old at time of diagnosis. It is a systemic, chronic condition that has retinal complications. Yearly ophthalmic cons...
Effect of Low Carbohydrate Diet on Type 2 Diabetic Patients and Usefulness of M-Value
Background: Debate between the Calorie Restriction (CR) and Low-Carbohydrate Diet (LCD) has been continued for several years. We have started LCD therapy for diabetic patients since 1999, and experienced good response to...
Glycemic Variations after Ingestion of Different Carbohydrate-Containing Foods Assessed by Continuous Glucose Monitoring in Healthy and Diabetic Individuals in Daily Life
Carbohydrate counting is a meal planning approach for diabetic patients, but individual variations of the effect of glycemic index do not seem to be well taken into account. Here we assessed glycemic variations after the...
Combination Treatment with a Novel Polyherbal Formulation and Metformin: A Single Blind Placebo-Controlled Study in Patients with T2DM and Cognitive Impairments
Background: Older people suffering from Type 2 Diabetes Mellitus (T2DM) are at major risk for age related cognitive dysfunction and dementia, mainly due to vascular complications. Studies have shown that T2DM is also ass...